Kittanning

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab monotherapy as the first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors express high levels of PD-L1. This Phase III, randomized, double-blind, multicenter global study focuses on patients with mNSCLC without certain genetic mutations who are suitable for this treatment approach. Participants are randomly assigned to receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle. The study compares these two drugs over repeated treatment cycles as first-line therapy. Both treatments are biological agents given by infusion, and the study is designed to monitor their effects over up to approximately five years. During the trial, participants will undergo regular assessments including physical exams, imaging scans such as CT or MRI to measure tumor lesions, and laboratory tests to evaluate organ function. Researchers will closely monitor overall survival, progression-free survival, treatment response, duration of response, and patient-reported outcomes on physical functioning and quality of life. Safety and immunogenicity of rilvegostomig will also be evaluated. Participants are followed and assessed for up to five years to gather comprehensive data on treatment effects and long-term outcomes.

Researchers are evaluating the effectiveness of four different dehydrated complete human placental membrane products, known as Cellular, Acellular, Matrix-like Products CAMPs, combined with standard care versus standard care alone in healing hard-to-heal diabetic foot ulcers. This study uses a unique modified platform trial design to compare multiple skin substitute products within one clinical trial. The goal is to achieve complete wound closure of diabetic foot ulcers over a 12-week period. Participants will be randomly assigned to receive one of the four placental membrane productsRevita, Relese, Cogenex, or Enverseeach applied weekly alongside standard care, or to receive standard care alone. Standard care includes cleaning, debridement, moisture balance for the ulcer, and offloading to reduce pressure on the foot. Treatments continue weekly until the ulcer heals or up to 12 weeks, whichever comes first. During the study, participants will attend weekly visits for treatments and assessments. Researchers will monitor the percentage of ulcers that fully close within 12 weeks, the time it takes for ulcers to close, reduction in ulcer size, pain changes, adverse events, and improvements in quality of life. The study includes detailed evaluations such as imaging of ulcers and vascular assessments to ensure adequate blood flow. Participants safety and wound healing progress will be closely followed throughout the trial and up to 14 weeks.